About: Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.04 (-10.32%)
JAGX NASDAQ Jaguar Animal Health Inc
Jaguar Animal Health Inc share price
JAGX price activity
Último preço
$ 5,040
Variação (24h)
-0,58 USD (-10,32%)
Volume
595.21K
Volume (média 4 sem.)
-
Abertura
$ 5,24
Variação do dia
$ 4,91 - $ 5,50
Fechamento anterior
$ 5,62
Último negócio
07 Oct, 2:59 pm GMT+0
Atrasado
07 Oct, 2:59 pm GMT+0
JAGX price performance
Atrasado
07 Oct, 2:59 pm GMT+0
quote.marketSignals